Latest literature

Cancer research papers

Nightly index of recent papers from PubMed, bioRxiv, and medRxiv. Filters are designed for both researcher precision and patient-friendly navigation.

Learn how we rate papers in our methodology.

Starting focus

Cholangiocarcinoma

We’re indexing all cancers but highlighting cholangiocarcinoma while the evidence atlas expands.

View cholangiocarcinoma papers

Cancer family

Cancer type

Subtype

Topic

Modality

Study type

Source

Peer-reviewed

Date from

Date to

Sort

Min rating

2 papersSorted by most recent

Discovery of Novel ERK5 Inhibitors for Pancreatic Cancer via a Virtual Screening Approach.

ACS medicinal chemistry letters • 2026-02-12 • DOI: 10.1021/acsmedchemlett.5c00547

Peer-reviewedImpact 73

Topics

Treatment, Screening / Early detection, Biology / Mechanism, Outcomes / Survival

Modality

Targeted therapy, Chemotherapy, Imaging

Study type

Lab / Preclinical

Abstract

Pancreatic ductal adenocarcinoma (PDAC) exhibits a dismal prognosis, with limited therapeutic options beyond first-line chemotherapy. Extracellular signal-regulated kinase 5 (ERK5) represents a compelling therapeutic target, particularly due to its compensatory role in sustaining proliferation and MYC stability following ERK1/2 inhibition in KRAS-mutant PDAC. To…

Authors

Jingyu Zhang, Xinle Yang, Bingqian Huang, Yingxuan Xu +7

AI-generated summary

Discovery of Novel ERK5 Inhibitors for Pancreatic Cancer via a Virtual Screening Approach. reports: Pancreatic ductal adenocarcinoma (PDAC) exhibits a dismal prognosis, with limited therapeutic options beyond first-line chemotherapy. Extracellular signal-regulated kinase 5 (ERK5) represents a compelling therapeutic target, particularly due to its compensatory role in sustaining proliferation and MYC stability following ERK1/2 inhibition in KRAS-mutant PDAC. To address the need for novel inhibitors, we implemented an integrated virtual screening workflow combining PSICHIC screening, KarmaDock, similarity analysis, molecular clustering, and manual selection.

This summary may be inaccurate. Verify with the primary paper.

Primary source: PubMed.

AI-HOPE: An AI-Driven conversational agent for enhanced clinical and genomic data integration in precision medicine research

genetic and genomic medicine • 2025-02-22 • DOI: 10.1101/2024.11.27.24318113 • Published in 10.1093/bioinformatics/btaf359

PreprintImpact 59

Topics

Biology / Mechanism, Outcomes / Survival

Modality

Imaging

Study type

Observational

Abstract

Introduction: The increasing complexity of clinical cancer research necessitates the development of automated tools capable of integrating clinical and genomic data while accelerating discovery efforts. Artificial Intelligence agent for High-Optimization and Precision mEdicine (AI-HOPE) is introduced as an innovative conversational AI platform powered by…

Authors

Yang, E.-W., Velazquez-Villarreal, E.

AI-generated summary

AI-HOPE: An AI-Driven conversational agent for enhanced clinical and genomic data integration in precision medicine research reports: Introduction: The increasing complexity of clinical cancer research necessitates the development of automated tools capable of integrating clinical and genomic data while accelerating discovery efforts. Artificial Intelligence agent for High-Optimization and Precision mEdicine (AI-HOPE) is introduced as an innovative conversational AI platform powered by Large Language Models (LLMs), designed to empower domain experts to perform integrative data analyses through natural language input, eliminating the need for programming expertise. AI-HOPE offers robust analytical capabilities, enabling the generation of actionable insights in clinical and translational research. This is a preprint and not peer reviewed.

This summary may be inaccurate. Verify with the primary paper.

Primary source: medRxiv (not peer reviewed).